Reviva Pharmaceuticals Reports Q2 2025 Financial Results
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has recently shared its financial performance for the second quarter ending June 30, 2025, alongside several exciting business milestones that signal progress for the Company.
Positive Clinical Trials and Safety Profile
The Company announced that the brilaroxazine program, which aims to treat schizophrenia, has reached significant milestones, most notably the successful completion of a 12-month open-label extension trial. This trial demonstrated a well-tolerated safety profile along with robust efficacy across various symptoms. These results are pivotal as the company moves forward toward potential drug registration.
Key Business Highlights from Q2 2025
Dr. Laxminarayan Bhat, the CEO of Reviva, highlighted that the Company has been progressing towards filing a New Drug Application (NDA) with the FDA. The successful completion of the Phase 2 and Phase 3 trials provides valuable data, which will be crucial for the upcoming FDA discussions planned for the fourth quarter of 2025.
Financial Performance Overview
During the second quarter, Reviva reported a net loss of approximately $6.1 million, or $0.12 per share, marking an improvement from a net loss of around $7.9 million, or $0.26, during the same period last year. Cash and cash equivalents as of June 30, 2025, amounted to approximately $10.4 million, which positions the Company well for future endeavors and clinical trials.
Future Steps and Strategic Goals
Going forward, Reviva is planning to submit the NDA for brilaroxazine in Q2 2026, contingent upon receiving favorable feedback from the FDA. The Company is also preparing to initiate a registrational Phase 3 RECOVER-2 trial for schizophrenia as soon as regulatory guidance is received. Additionally, Reviva aims to explore partnership opportunities that could bolster its pipeline development, including a new formulation of brilaroxazine tailored for psoriasis.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals is dedicated to developing innovative therapies targeting central nervous system disorders, alongside other unmet medical needs, through both brilaroxazine and its second candidate, RP1208. The Company has secured patents for these compounds across various jurisdictions, reinforcing its commitment to advancing healthcare solutions.
Frequently Asked Questions
What is the main focus of Reviva Pharmaceuticals?
Reviva Pharmaceuticals is focused on developing therapies for conditions related to the central nervous system, as well as inflammatory and cardiometabolic diseases.
What were Reviva's reported losses in Q2 2025?
The Company reported a net loss of approximately $6.1 million, which is a reduction compared to the previous year's loss of around $7.9 million.
What are the upcoming milestones for Reviva?
Reviva plans to submit its New Drug Application (NDA) for brilaroxazine in Q2 2026 and is preparing for a Phase 3 clinical trial for schizophrenia.
How is Reviva's financial position as of June 2025?
As of June 30, 2025, Reviva's cash and cash equivalents totaled approximately $10.4 million, providing a solid financial foundation for upcoming projects.
What are Reviva's long-term goals for its drug candidates?
The Company aims for both brilaroxazine and RP1208 to fulfill unmet medical needs while pursuing patent protections that may ensure market exclusivity for many years.
